Our Story

Darou Darman Arang is a fast growing pharmaceutical Company in Iran.

Darou Darman Arang is a fast growing pharmaceutical Company in Iran.

DAROU DARMAN ARANG acts as the representative agent for specialty, rare disease, biotech and vaccine producing companies looking to penetrate to Iran. We are the preferred strategic partner, providing turn-key solutions and support for their commercial operations. We provide, in an efficient manner, the full commercial infrastructure, including pharmaceutical in-licensing, registration, distribution, sales and marketing. Combined with our commitment to evidenced-based medicine and to the highest international business standards, our expertise and regional knowledge are a significant added value for organizations with a growth agenda.

Our Story

Research & Development Department

We in R&D department aimed to Reach to various market requirements and high quality products, by representing formulation and providing new method analysis, taking advantage of experienced Experts, using the most up to dated sources of pharmaceuticals and advanced devices. In addition to exploitation of cooperation and consultation of prominent University professors and other authentic science centers.

Read More

Activities

Regulatory

Having sufficient knowledge of drug registration rules & regulations for registration of products
Adequately capability of registering new products in the Drug National List
Well knowledge of the drug, raw material and food supplement approval process and registration bureaucracy in Ministry of Health
Submitting registration documents to MOH

Read More

DAROU DARMAN ARANG COMPANY WAS ESTABLISHED BY A GROUP OF EXPERIENCED PEOPLE TO ATTRACT, DEVELOP AND DELIVER NEW CAPABILITIES.

Featured products

Latest news

[ News Archive ]

13 Jan

FDA issues final guidance on pharmacology data for biosimilarity

The US Food and Drug Administration (FDA) on 29 December 2016 published final guidance outlining the clinical pharmacology data necessary to support a biosimilar application.

13 Jan

Benepali gains approval for extra indications

Samsung Bioepis, which is a joint venture between South Korean electronics giant Samsung and biotechnology company Biogen, announced on 16 December 2016 that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) had adopted a positive opinion for the extension of indications for its etanercept biosimilar Benepali

13 Jan

UK competition authority accuses Actavis of overcharging NHS

The UK’s Competition and Markets Authority (CMA) has accused Actavis of breaching competition law by increasing the price of generic hydrocortisone tablets by more than 9,500−12,000% compared to the brand-name product, which was sold by a different company prior to April 2008.

Copyright © 2017 Darou Darman Arang Co. All rights reserved.